Coherus reduces ATM equity offering capacity from $150M to $63.75M

Coherus Oncology, Inc.

Aggregate offering price under ATM with Cowen reduced by $86.25M, from $150M to $63.75M.
Amendment No. 1 to November 2022 Sales Agreement executed on May 15, 2023.
Remaining capacity of $63.75M remains available for future at-the-market sales.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Coherus Oncology, Inc. amended Amendment No. 1 to Sales Agreement with Cowen and Company, LLC valued at $86.25 million (effective 2023-05-15).

Action: amendment
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: $86.25 million
Effective: 2023-05-15

Exact text from the filing

reduced the amount of shares that could be issued and sold pursuant to its “at-the-market” program (“ATM”) with Cowen and Company, LLC (“Cowen”) in an amount equal to $86.25 million.

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-145220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.